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INTRODUCTION 
Verapamil was first introduced in the early 1960's as a smooth muscle relaxant with 
potent vasodilator properties.1 Antiarrhythmic effects  were demonstrated in the mid-1960's, 
but it V83 not until August, 1981 that the Food awl Drug Administration (FDA) approved the 
intravenous form of the drug for clinical use. This action was followed by marketing of the oral 
form as an antianginal medication in March, 1982. Therapeutic benefits of verapamil have 
been attributed to its ability to block slov calcium channels, and m the years following Its 
release, nifedi pine and diltiazem, tvo agents vith si milar action, were given FDA approval. 
Regulation of calciurn is vital to a vide range of physiologic functions which include 
myocardial contractility, nerve impulse transmission, smooth muscle contraction and the 
secretory activity of exocrine glands. In the smooth muscle cell, calcium plays a dual role in 
excitation-contraction coupling. An excitatory impulse results in movement of extracellular 
calci urn i nto the cell where it serves asasti mul us to i nitiate the release of i ntracell uler stores 
of calci um from the sarcoplasmic reticulum. Once released, free cytoplasmic calcium binds to 
the regulatory molecule troponin and removes its inhibitory effect  on actin and myosin, allowing 
them to interact and produce a contraction. The concentration of free intracellular calcium 
determines the degree of contraction of the entire muscle fiber.2 
Intracellular stores of calcium are much greater in skeletal muscle than in cardiac and 
smooth muscle, therefore skeletal muscle is less affected by extracellular shifts of calci um into 
the cell. Conversely, cardiac ami smooth muscle are dependent on transmembrane fl ux, 
requiring continual replenishing of calcium from extracellular sites. This dependency permits 
manipulation of the activity of these cells by calcium channel blockers.1 Pharmacologically, 
the calcium channel blocker (CCB) drugs act to prevent excitation-contraction coupling, 
primarily by blocking the transmembrane movement of calcium ions.1-2 
The CCB agents ire a heterogeneous group of drugs that differ  greatly in chemical 
structure and side effect  profiles. Although much has been written about thei r varied side 
effects  and therapeutic indications, limited information exists concerning their toxicity. 
Twenty-one human exposures describing overdoses with CCB agents have been reported in the 
English literature since 1 9 7 7 . 3 - 2 0 In 1984, Skoutakls and associates 3 reviewed six of the 
17 literature reports then available and identified characteristic signs and symptoms in these 
poisoned patients. Specific therapeutic interventions were recommended by the authors, but 
the cli nical utility of these recommendations was not confi rmed. Clearl y, more i nfor nation 
about the toxicity of these agents was needed. Recently, an untapped resource of information 
about the toxicity of a wide range of agents, i ncluding CCB drugs, has become available, the 
American Association of Poison Control Centers (AAPCC) National Poisoni ng Data Base. This 
data b»e contained information on 730,224 human poison exposures during calendar year 
1984. Four hundred eighty-one of these exposures Involved CCB agents.21 A review of the 
information on human exposures in the AAPCC database should provide additional 
epidemiological and toxicological data on CCB exposures not previously available. 
The purpose of this research project was to retrospectively review the symptomatic 
CCB exposures reported to the MPCC during calendar year 1984 and to descri be the 
demographic characteristics, symptoms, treatment and outcome of acute overdoses with 
verapamil, nifedipine and diltiazem. This description should provide useful information for the 
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health care provider about the management of patients vith a CCB overdose. 
Background Information 
The AAPCC tested a national, voluntary, data reporting system for poison control 
centersin 1983. The system was subsequently made available nationallyfor use by poison 
control centers i n 1984. The data collection system consists of: 
1) a medical record and data collection form; 
2) standard definitions for the data captured on the form; 
3) a uniform data collection technique; 
4) a uniform product identification  cote; 
5) centralized data processing. 
The AAPCC Cooperative Poison Center Report Form (Appendix A) is perforated 
vertically and separates Into a medical record maintained by the individual poison center, and a 
scannable data collection portion. The separate parts are identified by the same unique serial 
number which allows the computer data to be li nked to the medical record portion of the form. 
Participating poison centers submit their data to the AAPCC. Data may be sent to the AAPCC Data 
Compiling Organization on magnetic tape or computer disk or the data collection portion of the 
form may be sent to a central scanning service and then to the Data Compiling Organization. 
Data are compiled, analyzed and published yearly. 
When a poisoni ng case is received by a poison center, perti nent data are gathered by 
the Poison Information Specialist (PIS) and recorded on the form. Included are a brief written 
history, assessment of severity, symptoms, follow up notes and outcome. In addition, certain 
of these data are captured for entry into a computer data bank by darkening scannable bubbles 
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on the data collection portion of the form. The medical record portion of the form contains 
information not captured on the data collection portion of the for m such as the time of the 
exposure, an esti mate of the amount of product involved in the exposure, and the specific 
symptoms and duration of the symptoms experienced by the patient. Follow up gene rail y occurs 
until symptoms have resolved, and when the case is brought to closure, the PIS selects a medical 
outcome representative of the symptoms experienced by the patient. The follovi ng medical 
outcome choices are available: 
NO EFFECT: The patient developed no symptoms as a result of the exposure. 
MIM3R EFFECT: The patient exhibited some symptoms as a result of the 
exposure, but those symptoms were not life threatening. The symptoms 
resolved rapidl y and the patient returned to a pre-exposure state of veil 
being without residual disability or disfigurement. 
MAJOR EFFECT: The patient exhibited some symptoms as a result of the 
exposure. The symptoms were life threatening or resulted in residual 
disability or disfigurement. 
DEATH: The patient died as a result of the exposure or a direct complication 
of the exposure which was unlikely to have occurred had the toxic exposure 
not preceded the complication. 
UNKNOWN, NONTOXIC EXPOSURE: The patient was lost to follow up; however, 
the exposure was likely to be nontoxic because the agent involved was nontoxic 
or the amount of the exposure (or route) was insignificant and unlikely to 
result in toxicity. 
UNKNOWN, POTENTIALLY TOXIC EXPOSURE: The patient was lost to follow up 
and the exposure was significant and may have resulted in toxic 
manifestations. 
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The first four choices have known outcomes, i ndicati ng that poison center staff  were 
able to follow the patient until symptoms abated or the outcome could be reasonably 
determined. The last two choices allow the PIS to predict the medical outcome when follow up 
is not possible. These medical outcomes are captured on the computer scannable section of the 
form and may be accessed through the national data base. Retrieval and review of the medical 
record portion of tha data collection form of all CCB cases with a medical outcome other than 
"NO EFFECT" should provide information concern! ng patient characteristics, symptoms and 
treatment. 
METHODS 
The AAPCC allows access to data reported in the national database only with the 
permission of the reporting poison center. Therefore,  an initial letter was sent to 
poison centers in September 1985, requesting the cooperation of the center to allow 
access to data in the national data base. In October, centers not yet responding to this 
request were contacted by telephone, and verbal permission to 1 ncl ude them 1 n the 
study was obtained. Once permission was granted, the AAPCC forwarded a magnetic 
tape of all CCB exposures i n the 1984 data base. This magnetic tape contained the 
data captured as scannable bubbles on the data collection portion of the form. A 
computer print-out was generated from these primary data and the Information 
was utilized to identify symptomatic cases ami excl ude those with an outcome coded as 
"NO EFFECT". 
In November 1985, each Center was sent another letter (Appendix fl) with a list of 
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that Center's CCB exposures. The letter asked that Center to send a copy of the medical record 
portion of the specified form to the investigator. Patient confidentiality was assured; 
however, the poison center was allowed to omit the name and phone number of the caller and 
patient before submitting the copy. Centers not responding to the letter were contacted by 
telephone i n January 1986, and asked to send copies of the specified forms by March 1, 1986. 
The medical record portion of the data collection form served as a second source of data 
concerning CCB exposures during 1984. Information was primarily abstracted from this 
source because of the additional descriptive information available in this section. Each form 
was reviewed and data were abstracted and entered into a personal computer, in a standard 
format. Each case was searched for fifteen items: 
1) case Identification number 




6) time of call 
7) date of call 
8) time lapse since exposure 
9) product 
10) dose ingested 
11) treatment site 
12) presence of symptoms at ti me of poison center contact 
13) drug history 
14) signs and symptoms 
15) treatment 
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Unique designations were originally assigned to "positive findings", "negative 
findings", and "missing data". Using hypotension as an example, a "positive finding" 
vas defined as a systolic blood pressure less than 90 mm Hg or rotations of "hypotensive" 
on the medical record portion of the data collection form, while a "negative finding" 
would be represented by a blood pressure reading of 120/80 mm Hg or notes of 
"normotensive" on the record. The "missing data" category was used to designate 
a chart lacking information concerning the patient's blood pressure. The latter 
two categories were excluded after initial anal yses because "negative findings" were 
infrequently charted on the forms and "missing data" provided no useful information. 
Criteria were also developed to extract the <tese i ngested when a range of toes was 
noted on the form, for example, "20- 30 verapamil 80 mg." When this occurred, 
the lowest dosage was used in order to avoid overestimation of the mim mal toxic dose. 
When abstracti ng gastroi ntestinal signs and symptoms, a notation of vomiti ng was 
considered related to the CCB only if it occurred prior to use of gastrointestinal 
decontamination measures. 
The Statistical Package for the Social Sciences (SPSS) vas utilized to analyze 
the data. Cross tabulations were generated and chi-square analysis was performed 
during preliminary analyses. After implementation of an extensive case exclusion 
process, the 50 retraining cases did not meet the criteria for use of these analytical tests. 
Si mple descriptive anal yses including mean, range and frequency, were used because the data 
could best be described by these tests. 
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RESULTS 
Cardiovascular drugs comprised 6,740 of the human poison exposures reported to the 
AAPCC National Data Base during 1984. Four hundred eighty-one of these exposures involved 
CCB agents 2 1 and 50 (10.4S) of the CCB cases are reported here. Figure I illustrates the 
reasons for excl usion of the cases. Two hundred forty-two of the cases had a medical outcome 
categorized as "NO EFFECT"; these cases were excluded because the patients did not develop 
symptoms. Thirty-nine case reports were unavailable from six centers which refusal to 
participate in the study. Twenty-one cases were irretrievable by poison centers which agreed 
to participate. Seven cases, originally reported as CCB exposures, were excluded because 
the patient had not ingested a CCB; five cases were not submitted on the AAPCC form as 
requested; one case was an informational request rather than an exposure; one case was a 
duplicate entered into the data base twice; and one case involve! an animal exposure rather 
than a human exposure. 
Thus, 164 cases were reviewed and initially analyzed. This awl pis revealed 
the confusing nature of Information about symptoms, treatment and outcome on the forms 
where CCB drugs were taken concurrently with another drug. Frequently, it was not 
possi ble to determine if the symptoms reported were attributable to the CCB, the other 
agent taken concurrent! y or to some i nterective effect.  Therefore,  43 cases were 
excluded. It also became apparent that exposures with "UNKNOWN" outcomes 
lacked follow up and specific information. Subsequently, 71 cases with 
"UNKNOWN" outcomes were also excluded leaving 50 cases which were analyzed 
and reported. Twenty poison centers representi ng 17 states contributed these 
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50 cases. 
Table I lists the age, sex and reason for exposure by product. The patients studied 
ranged in age from one to 73 years vith a mean of 25.5 years. Seventeen (3451) of the 
exposures involved children less than five years of age; eight children were one par of age, 
seven were two years old, and the remaining two were four years old. Thirty-one subjects 
were adults with a mean age of 41 years, however, the age was not recorded in seven cases. 
Two patients, each 15 years old, were Included in the adult category for analytical purposes. 
Eighteen (36.7$) subjects were male, 31 (63.3%) were female, and the sex was unrecorded 
in one pediatric case. Females predominated in the adult category by a ratio of two to one, 
while the children were equally divided by sex. 
Dlltlazem was Ingested 1n seven cases ( 1 4 $ ) , nifedipine was ingested in 13 
cases (26%) and verapamil accounted for the remaining 30 cases ( 6 0 1 ) . All children 
accidentally ingested the medication, 18 adults intentionall y overdosed, 10 adults 
accidentally overdosed and five patients experienced an adverse drug reaction to a 
prescribed therapeutic dose. Seven of the 17 children were found to have ingested a 
grandparent's medication and 21 of the 33 adults i ngested medication prescribed for 
them. This includes six of the 18 patients intentionally overdosing vith a CCB. 
Eight subjects were prescribed the medication for control of angina or cardiac 
arrhythmias, three received the medication for rnlgral ne headache, while the 
diagnosis was unknown for the remaini ng ten cases. It is likel y that many of these 
patients had been taking their medication chronically before the overdose occurred 
since the medication was noted to be newly prescri bed i n only four cases. 
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The time which had elapsed between the patient's exposure and initial contact with the 
poison center was recorded for 38 of the acute ingestions and is described in Table II. 
Twenty-one percent of the incidents happened "now" or "just prior to the call". Thirty-four 
percent of the callers contacted the poison center within five minutes of the exposure arid 5 8 $ 
sought help by 30 minutes. Within one hour of the exposure, 71 % of the calls had been 
received, 8 2 $ called within two hours, 8 7 $ within three hours, 9255 by four hours, and 
91% had teen received within six hours of the exposure. Excluded from the table were four 
adult exposures which occurred over an extended period of time, five cases for which the time 
since ingestion was unknown, and three cases for which the time was unrecorded. 
When a child was involve! in an exposure, contact with the poison center was 
established more quickly than with adults. An average of 15 minutes elapsed between exposure 
and a call to the poison center for pediatric cases while the average time increased to 117 
mlnutes for the adult group. When 1 ntentlonal overdoses were anal yzed separately, the average 
time to contact the poison center increased to 182 minutes while adults with accidental 
ingestions called an average of 27 minutes after the exposure. 
Table III lists the average dose of drug ingested by the patient for the pediatric and 
adult groups. Only 37 of the 50 patients had this 1 nformation recorded. 1 n children, the 
average dose was 38 mg.for dilt1a2em, 10 mg. for nifedipine and 710 mg. for verapamil. The 
average amount of drug ingested by adults was 60 mg. for diltiazem, 87 mg. for nifedipine, and 
2,871 mg.for verapamil. When suicidal patientswere considered separately, the average dose 
increased to 225 mg.for nifedipine and 3,677 mg.for verapamil. 
One patient ingesting nifedipine exceeded the maximum daily therapeutic dose, 
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but verapamil vas the only product 1 ngested 1 n an average amount which exceeded this maximum 
recommended dose. Children ingested 1.5 times the maximum daily adult dose on average, but 
one child vho ingested less than four times the maximum therapeutic daily dose died. Verapamil 
is approved for pediatric use as an intravenous drug, but oral pediatric dosing guidelines are not 
available for any of the CCB drugs. On average, the adults ingested six times the maximum 
daily therapeutic dose. When analped separately, those patients intentionally overdosing 
influenced this average by ingesting eight times the maximum daily therapeutic dose. 
The mi rri mal toxic dose of diltiazem i n children was 60 mg. which produced a 
petecchial rash and arrhythmias in a two year old child. The ingestion of 10 mg. of nifedipine 
produced symptoms in three children; one became drowsy, another exhibited facial flushing and 
a third developed hypotension. Verapamil produced spontaneous vomiting in one child and 
'tiredness" in another following the ingestion of less than one tablet; the ingestion of 240 mg. 
byatvo year old child produced cardiac arrhythmias. A dose of 1,600 mg. in a 15 month old 
male resulted in <teath. Some adults experienced an adverse drug reaction from a 
therapeutically presented dose of their own medication; 60 mg. of diltiazem produced transient 
dizziness and shakiness in one patient ami a headache in another; a dose of 80 mg. of nifedipine 
produced transient mild hypotension in an adult and a dose of 80 mg. of verapamil in an adult 
produced transient central nervous system depression, heart rate changes and mild hypotension. 
More serious effects  occurred at the upper end of the therapeutic dosing range; intentional 
overdoses of 150 mg. of nifedipine and 480 mg. of verapamil in adults produced more severe 
hypotension requiring intravenous fluids to correct the condition. Vasopressors were also 
required 
to treat severe hypotension produced after an ingestion of 800 mg. of verapamil, and a 
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dose of 1,920 mg. resulted in death in a 37 year old female. 
Thirty ( 6 0 $ ) of the patients had developed symptoms by the time a call was placed to 
the poison center. Thirteen were asymptomatic at initial assessment, while this information 
was missing for the remaining seven cases. All patients eventually developed symptoms. 
Table IV lists the toxic effects  which occurred 1 n these 50 symptomatic patients. Forty-four 
percent of the subjects studied developed cardiovascular effects.  Eleven (21.6$) of the 
subjects demonstrated changes i n heart rate. Five developed bradycardia, while six patients 
were tachycardic. All of these patients had taken verapamil. Nineteen patients ( 3 8 $ ) 
exhibited hypotension after 1 nesting a CCB; two of these were children. This includes half 
(15 of 30) of the verapamil patients and one-third (4of13) of the patients exposed to 
nifedipine. None of the subjects ingesting diltiazem became hypotensive. Thirteen patients 
( 2 6 $ ) developed abnormal electrocardiograms during the course of the exposure. A two year 
old child had blocked paroxysmal atrial tachycardia, an Irregular 5-T segment, a prolonged P-R 
interval and experienced bigeminy for 20 minutes after ingesting 60 mg.of diltiazem. The 
remaining 12 patients developed arrhythmias after ingesting verapamil. These included four 
patients with junctional rhythm; one child with A-Y dissociation, prolonged P-R interval and 
variable block; another patient exhibited Mobltz II type arrhythmias concurrent with A-Y 
dissociation; one patient had paroxysmal atrial contractions; and another demonstrated first 
degree heart block. The remaining abnormalities, demonstrated in four patients, were a 
widened QRS interval, ventricular fibrillation, ventricular tachycardia and "multiple cardiac 
arrhythmias" noted 1 n the child who died. 
Central nervous system effects  occurred in twenty-four subjects ( 4 8 $ ) . These 
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symptoms were described ss lightheadedness, dizziness, headache, shakiness, sleepiness or 
drowsiness, lethargy, ataxia, agitation and combativeness. Those persons ingesting nifedipine 
were most likely to experience these effects;  ten of the 13 subjects exposed to nifedipine had 
central nervous system symptoms. Verapamil produced central nervous system effects  i n 11 
patients while these effects  occurred in three patients taking diltiazem. Only 18% of the 
children manifested central nervous system effects  while 64% of the adults had these effects. 
Four patients developed dermal reactions after i ngestion of a CCB. A two year old child 
exhibited "red lips "and developed petecchiae across his chest after ingesting 60 mg. of diltiazem 
and a 66 year old woman developed pruritis and a macular rash over her trunk and extremities 
after two weeks of chronic therapy with diltiazem. Two patients ingesting nifedipine also 
manifested dermal effects.  An 18 month old female developed red, tot cheeks, red eyes and cold 
hands after sucking on a 10 mg. capsule of nifedipine,and a 55 year old male was "flushed all 
over" after taking two Procardia® which he mistook for Doan's Pills®. 
Eleven (22%) subjects, two ingesting nifedipine and nine exposed to verapamil, 
developed gastrointestinal symptoms; four of these were children. Nausea and spontaneous 
vomiting were the symptoms noted, although one child who died after ingesting 1,600 mg. of 
verapamil had diffuse gastrointestinal hemorrhage on autopsy. 
A total of six effects  listed as other occurred in four patients. Metabolic abnormalities 
were documented on the records of two patients (4%). An adult ingesting 6,000 mg.of 
verapamil had a serum glucose concentration of 349 mg./dl. ami a child ingesting 1,600 mg.of 
verapamil had a serum potassium of 10 mEq/1. This same child developed acute renal failure 
and adult respiratory distress syndrome prior to his death. The second adult demonstrated 
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cyanosis of uncertain etiology requlring i ntubation and a thi rd developed digital ischemia. 
Table Y ill ustrates the reason for exposure, treatment site, and disposition of the 50 
patients. Thirty-six (72%) patients vere evaluated and treated in an emergency department; 
25 adults and eleven children are in this group. Twenty-one patients, 16 adults and five 
children, vere subsequently admitted 8s Inpatients for continued care, while 12 patients vere 
treated and released from the emergency department, and three patients died. All 18 of the 
adults intentionally overdosing vith a CCB vert evaluated at a health care facility; 15 vere 
admitted for medical care, one vas admitted for psychiatric eval uation, and tvo patients died. 
These latter tvo patients did not survive treatment beyond the emergency room. The pediatric 
death occurred in the intensive care unit. 
Table Yl shovs the number of patients receiving gastrointestinal decontamination and 
the specific therapy used. Forty-four  percent of patients received some type of gastrointestinal 
decontamination. Although these treatments vere frequently recommended by the PIS, It could 
not be determined if gastrointestinal decontamination vas utilized for the remaining 28 patients. 
Sixteen patients ( 3 2 $ ) received ipecac syrup; five adults and eleven children are included in 
this group. Four adults and one child received gastric lavage; the child also received ipecac 
syrup. Nine adults and tvo children vere given activated charcoal, while four adults and three 
children received a cathartic. Only four patients, tvo adults and tvo children, received full 
gastrointestinal decontamination vhich includes ipecac or lavage, followed by activated charcoal 
and a cathartic. 
Although all patients developed symptoms, not all patients required treatment. Table Yll 
lists specific treatments used in 21 of the 50 patients. Seven patients, vho had all ingested 
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verapamil, vere given calcium salts for treatment of hypotension or arrhythmias. Four of 
these patients, including one 18 month old child who developed arrhythmias after ingesting 
verapamil, received calcium gluconate; hovever, the dose vas undeterminable. Tvo patients 
received unspecified "calcium", vith dosage not recorded. One patient received calcium 
chloride, vhich reverted a videned QRS interval, although this patient later died. 
Seven adults (14%) received a fluid challenged increase blood pressure; tvo of these 
patients had taken nifedipine and five had ingested verapamil. Five patients received normal 
saline, hovever, the type of fluid replacement vas unspecified in the other tvo cases. Tvo 
patients ingesting nifedipine and one ingesting verapamil, had a positive response to this fluid 
challenge arid required no further  treatment for hypotension. Nine patients received 
vasopressors for hypotension, four after receiving a fluid challenge; all patients had ingested 
verapamil. Seven patients received dopamine alone; one patient received isoproterenol plus 
dopamine and one patient received Isoproterenol awl norepinephrine. These latter tvo patients 
died; these same tvo patients had pacemakers inserted. One patient vas "defibrillated for atrial 
fibrillation"; three patients received cardiopulmonary resuscitation but ultimately died. 
Six patients received five medical treatments other than those previously noted. One 
patient, vho developed a rash after taking diltiazem chronically, vas prescribed 
diphenhydramine and triamcinolone acetonide for the reaction. Five patients ingesting 
verapamil received other remedies; tvo vere prescribed oral fluids, one patient received 10 
units of insulin for an elevated blood gl ucose, another received lidocaine for ventricular 
tachycardia; and an unspecified extracorporeal method to enhance verapamil elimination vas 
attempted in the child who died. 
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DISCUSSION 
During 1984, the AAPCC gathered date on 481 exposures to CCB agents. Fifty of 
these cases i n which the outcome was known and follow up occurred have been reviewed. 
This report best describes the effects  of verapamil since this drug was ingested 
consistently in much larger amounts than nifedipine and diltiazem. Verapamil was 
ingested predominantly by adults with suicidal intent. The tvo hour average time delay 
between exposure and poison center contact for the adult cases i rrficates the purposeful 
intent of many of these adult patients, since suicide attempters tend to delay in seeking 
medical attention. 2 3 The delay in contacting the poison center would also 
contribute to a greater likelihood of serious symptoms developing si nee greater 
absorption of the medication could occur. The large number of suicidal patients 
admitted for medical care also reflects the serious nature of the large doses ingested. 
Minimal toxic doses of CCB agents, based on cases described in this report, are 
within the therapeutic dosage range. The five patients who experienced an adverse drug 
reaction after ingesting a therapeutic dose, and the ten adults who mistakenly took a 
double-dose of their own medication and developed symptoms demonstrate the low 
therapeutic index of the CCB drugs. More serious effects  occurred for both nifedipine 
and verapamil at the upper limit of the recommended daily therapeutic dosing range. 
The manufacturer  of nifedipine recommends a daily dose of 120-180 mg. A 50 year 
old female with a history of unspecified cardiac disease ingested 150 mg. of nifedipine 
and required treatment for the hypotension that occurred. The maximum 
recommended daily dose of verapamil is 480 mg; an adult ingesting this dose developed 
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gastrointestinal symptoms and hypotension requiring treatment vith intravenous 
fluids. 
A difference  appeared among the three CCB agents in the frequency of occurrence 
of central nervous system effects.  Patients 1 ngesti rig nlfedl p1 ne ex hi bited a 7 7 $ 
frequency of these symptoms as opposed to 4 3 $ for diltiazem and 3 7 $ for 
verapamil. At therapeutic doses, nifedipine also demonstrates the highest incidence 
of central nervous system effects  vith a rate of B - 2 6 $ reported for dizziness and 
headache.24 
When reviewing supportive treatments used for the 50 study patients, an 
appropriate explanation for the small percentage of patients receiving some type of 
gastrointestinal decontamination is likely tvofold. First, 15 patients presented vith 
symptoms after ingesting a double dose or taking a therapeutic dose of a nevly 
prescribed medication. Si nee the number of tablets or capsules ingested vas snail, the 
expected yield from gastrointestinal decontamination vould be minimal. Hone of these 
study patients received any form of gastrointestinal decontamination. Second, a larger 
number of patients actually may have received gastrointestinal decontamination than 
vas documented. For those patients treated i n a health care facility, i pecae syrup or 
lavage, activated charcoal and a cathartic, vere recorded consistently as recommended, 
but documentation concerni ng the actual admi nistration of these therapies vas often 
lacking. 
The most frequently utilized form of decontamination vas induction of emesis vith 
ipecac syrup. In a fev instances, lavage vas recommended in preference to induction of 
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emesis with i pecac syrup because of the possi bility of rapid onset of central nervous 
system depression or cardiovascular complications. This is especially important for the 
pediatric patient who chews nifedipine soft gelatin capsules, the contents of which are 
absorbed sublingual^ and have an onset of effect  estimated in minutes.24 Oms 18 month 
old female who sucked on a nifedipine capsule developed red cheeks within 20 minutes 
and appeared dizzy 40 minutes after the ingestion. This rapid onset of effect  may prove 
lethal to patients taking large overdoses. If serious symptoms develop withi n one-half 
to two tours after exposure, the optimal benefits of gastrointestinal decontami nation 
may be hi ndered when treatment is delayed. Early administration of gastrointestinal 
decontamination is especially important for overdoses involving drugs with a rapid 
onset of effect  such as the CCB agents. 
The role of calel urn salts as antidotes for CCB overdoses 1s currentl y unknown. 
Calcium salts are frequently recommended to treat hypotension and cardiac 
dysrhythmias associated with CCB overdoses, but actual evidence to support their 
efficacy is conflicting. Several authors 3.6,9.; 1,12.16-19 attributed the clinical 
improvement of their patients to the administration of calcium salts, although closer 
scrutiny revealed that intravenous fluids, vasopressors, or other therapeutic 
interventions were used simultaneously.. Thus, the improvement could not always be 
definitively attributed to the administration of calcium salts. Others administered 
calcium salts without comment as to their effect  8 , 1 5 and a third group noted a distinet 
lack of therapeutic benefit when calcium salts were g i v e n . 1 0 , 1 3 Several mechanisms 
exist by which CCB drugs may prevent excitation-contraction coupling, yet it is not 
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known If any of these mechanisms can be competitive! y reversed by the addition of 
calcium salts. Further research is needed to determine the role of calcium salts as 
antidotes i n CCB overdoses. 
When reviewing the cases in which patients required treatment for hypotension, 
it is likely that the use of a fluid challenge as a specific treatment is under reported. 
Standard treatment for acutely hypotensive patients in a hospital is to place the 
patient in the Trendelenberg position, followed by an intravenous fluid challenge and 
administration of vasopressors, if necessary. Only four patients were noted to have 
received a fluid challenge prior to the administration of vasopressors, yet nine 
patients received vasopressors. Si we two patients ingesting nifedipine and one taking 
verapamil responded to a fluid challenge, the number of patients receiving a fluid 
challenge should exceed those receiving vasopressors. Only ore patient was noted to 
have been placed in the Trendelenberg position. Eleven of nineteen patient developing 
hypotension received a fluid challenge or vasopressors or both, suggesting that 
hypotension was clinically significant in greater than half of the patients. 
Three of the four deaths identified In the rational data base are Included In the 
study cases and are described in detail in Appendix C. All deaths occurred after the 
ingestion of verapamil. The delay in seeking medical attention and receiving 
gastrointestinal decontamination nay be important in these cases. For example, a 15 
year old male ingesting 3,600 mg. of verapamil survived after arriving at a health care 
facility within 30 minutes of exposure. He immediately received gastrointestinal 
decontami nation. Another adult survived a dose of 6,000 mg. of verapamil with 
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prompt gastrointestinal decontamination and supportive care in the emergency 
department, although the time since ingestion vas unknown. Paramedics were 8t the 
scene 30 minutes after a patient ingested 21,600 mg. of verapamil, but rapid 
deterioration prevented gastrointestinal decontamination in this patient and he died. 
The other adult who died arrived at a health care facility at an unknown time after 
ingestion of 1,920 mg. of verapamil. Inability to stabilize this patient also precluded 
the administration of gastrointestinal decontamination measures. The pediatric 
death occurred after Ingestion of 1,600 mg.of verapamil. The time of ingestion 
and use of gastrointestinal decontamination were unknown in this case. One of 
the 50 cases appears to contradict the argument that prompt gastrointestinal 
decontami nation is important to survival of the patient. A 19 year old female who 
ingested 5,600 mg. of verapamil and was not evaluated at a health care facility until 
eleven hours after exposure did not develop severe toxicity; she was described as 
"shaky and dizzy and vomiting all night". By her history, she was treated and released 
after an unspecified cardiac evaluation was performed in the emergency room. Although 
gastrointestinal decontamination measures were not utilized in this case, reasons which 
can be suggested to account for the mild course exhibited by this patient incl ude 
inaccurate estimate of the amount ingested, or prolonged vomiting and subsequent 
removal of the drug secondary to this effect.  In spite of this case, early utilization 
of gastrointestinal decontamination techniques and prompt referral  to a healthcare 
facility are prudent measures to be considered after ingestion of a large amount of 
verapamil. 
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Some medications prescribed for adults, such as Lomotil® and Catspres® may 
be more toxic in children than adults.25' 2 6 Since the half-life  of verapamil may be 
longer in children than adults after an oral dose,2 7 an attempt vas mate to determine 
if pediatric subjects differed  from the adults. For the majority of the organ systems 
involved, children developed toxic effects  at a lover rate than the adults. None of 
the children developed heart rate changes, and a smaller percentage experienced 
hypotension and arrhythmias than the adults. The lover percentage of central 
nervous sptem effects  vhich occurred in the pediatric group may be explai ned 
by the subjective nature of these effects.  Central nervous system symptoms 
included headache, dizziness and lightheadedness, vhich are difficult  to assess in 
young children, although tvo parents reported effects  described as "dizziness, 
bumping into things", and "tiredness", and an emergency department nurse described 
a child as "sleeping". Effects  may also have occurred less frequently because of the 
quicker response time in the pediatric group. For accidental ingestions, the 
response time in children vas half that of the adult response time. Gastrointestinal 
decontamination measures Instituted earlier may have prevented absorption of the 
drug ingested. 
For those organ system effects  rarely reported, the pediatric sample is biased by 
the case involving the fifteen month old child vho died after ingesting verapamil. Three 
of his post-mortem findings vere unique: adult respiratory distress syndrome, acute 
renal failure ami diffuse gastrointestinal hemorrhage. This child also displayed 
hyperkalemia. No surviving patients vere knovn to exhibit any of these findings and 
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autopsy reports vere not available for the tvo adult deaths for comparison. These 
effects  cannot be directly attributed to the CCB although prolonged hypotension due the 
large dose of verapamil may have been contributory. 
Children experienced less severe symptoms than adults as evidenced by the 
mini mal treatment required. None of the children received a fluid challenge, 
vasopressors, or a mechanical pacing device, confirming the mild and transient 
nature of the hypotension and arrhythmias reported. The large number of 
children treated in a health care facility may be explained by the lack of FDA 
approval for pediatric oral use of the CCB drugs. Lack of therapeutic dosi ng 
guidelines and experience with these medications in the pediatric population 
may have resulted in referral  to a healthcare facility rather than observation in 
the home. 
Based on the cases reviewed in this report, the minimal toxic dose of CCB drup 
for pediatric patients appears to be a therapeutic adult dose. The average amount 
of CCB ingested by the pediatric patients was much less than that ingested by the adults, 
but a child died after ingesting 1es3 than four times the maximal 
therapeutic dally dose of verapamil. More accurate estimation of ingested 
doses should be based on a milligram per kilogram amount or serum drug 
concentrations. These calculations vere not possible since weights of victims 
were not routinely recorded and serum drug concentration assays are not readily 
available. 
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Comparison of Cases to Literature Reports 
The twenty-one literature caw reports 3 - 2 0 involving CCB ingestions have not been 
reviewed collectively. As seen in the study cases, the literature cases contained a large number 
of verapamil exposures. I n order to better describe overdoses by patients with suicidal intent 
ingesting verapamil, the literature cases were reviewed in a format similar to that utilized 
for analysis of the study cases. Eleven literature reports were excluded; seven cases 
involved polydrug exposures, one case each involved diltiaztm and nifedipine rather than 
verapamil, one case involved an accidental pediatric exposure and the last case was a 
pathology report. Ten of the literature reports and fifteen study cases involving verapamil 
were compared. 
The average age of patients reported i n the literature was 27 years (range 14-68) 
compared to a mean age of 32 years (range 15-59) for the fifteen verapamil cases reported 1 n 
1984. There were 11 females and four males in the study cases compared to seven females and 
three males in the literature series. These data correlate with the intentional nature of the 
ingestions; most suicide attempters are under 30 years of age and the predominance of female 
over male patients who attempt suicide occurs In almost all countries and time periods 
studied.22 The average dose ingested in the literature reports was comparable to that found in 
the AAPCC data base, 3,333 mg. in the literature end 3,683 mg. in the study cases. 
Cardiovascular effects  occurred most frequently in both the study cases and literature 
series with 92% of the patients develop! ng symptoms 1 n this category. Hypotension was the 
most frequent sign noted in 100$ of the literature cases, with arrhythmias occurring next at 
a rate of 9 0 $ ; hypotension and arrhythmias occurred at equal rates of 73$ in the study cases. 
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Heart rate changes occurred at a rate equal to arrhythmias for the literature patients but 
occurred in only 47% of the study patients. 
Effects  occurred i n a variety of other organ systems including the central nervous 
system vhere symptoms occurred in 48% of the combined cases. One patient in the literature 
series developed generalized tonic-clonic seizures after ingesting 2,000 mg. of verapamil. 
This effect  vas not reported in the study cases. Gastrointestinal symptoms vere reported in 
onl y 10% of the literature cases vhile one-thi rd of the study cases reported these effects. 
Hyperglycemia and cyanosis vere described in both groups, although occurring infrequently. 
Metabolic acidosis vas also described in the literature series. 
All patients in both series vere evaluated and treated at a health care facility. Half of 
the literaure patients received some type of gastrointestinal decontamination vhile this 
treatment vas recorded 1n 70% of the study cases. Only one patient in each series received full 
gastrointestinal decontamination. The benefit of early gastrointestinal decontamination and 
transport to a health care facility vith large ingestions of verapamil is supported in both series. 
The study cases include the tvo patients described earlier vho ingested 3,600 mg. and 
6,000 mg. of verapamil and survived vith prompt initiation of gastrointestinal decontamination 
procedures and supportive treatment at a health care facility. Another patient in the literature 
series survived after ingesting 5,600 mg.of verapamil. She received full gastrointestinal 
decontamination after transport to a health care facility, although the time betveen i ngestion 
and decontaml nation vas unknovn. 
Eighty percent of the literature patients and one-third of the study patients 
received intravenous calcium salts. As vith the AAPCC cases, several treatments vere given 
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concurrently vith the calcium salts in the literature cases. Clinical improvement could not 
alvay* tw attributed aolel y to the ad mi nistretion of calcium although many of the authors felt 
this to be t r u e . 3 ' 6 , 9 ' 5 1 In contrast to these claims, Immonen and covorkers 1 0 specifically 
described the lack of a therapeutic benefit from the administration of calcium gluconate in a 
68 par old female who ingested 6,400 mg. of verapamil; they concluded that the usefulness of 
calcium gluconate i n the treatment of verapamil poisoning needs further  study vith higher doses 
of calcium. This patient received a ten hour infusion of calcium gluconate in vhich 10 ml. of a 
10% sol ution vere infused every tvo hours. 
Toxic effects  requiring specific treatments developed n»3t frequently vithin the 
cardiovascular system in both series. A fluid challenge vas given to 2 0 $ of the literature 
patients and one-third of the study patients. Forty percent of the literature cases awl 60$ of 
the study cases reported the use of vasopressors. Dopamine predominated as the vasopressor of 
choice in both series, although some patients required the addition of a second vasopressor; 
isoproterenol vas used in five cases vhile norepinephrine, epinephrine and metareminol vere 
used in one case each. Four patients in the literature series received atropine for bradycardia; 
only one patient responded. Atroplne appeared 1 neffectlve 1 n 1 ncreaslng the heart rate 
sufficiently  to avoid the use of cardiac pacing devices since three of the four patients receiving it 
required pacemakers. Although the tvo study patients requiring pacemakers died, the 
literature series reports better success vith three of four patients survivi ng. 
One adult death occur red in the literature series.14 This case Involved a seventeen 
year old female vho vas admitted one to tvo hours after ingesti ng of an unknown amount of 
verapamil. She vas cyanotic, had fixed, dilated pupils, no detectable blood pressure and was 
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found to have complete heart Mock vith a rate of 30 beats per minute and narrow complex 
escape described on her electrocardiogram. She received i continuous infusion of calcium 
gluconate; dopamine, isoproterenol ami epinephrine vere administered to raise her blood 
pressure. Atropine vas given to increase her heart rate prior to insertion of a cardiac 
pacemaker. Cardiopulmonary resuscitation vas required. The patient died 19 tours after 
admission. The choice of vasopressors i n this case parallels their use in the other cases i n 
which they were required. Dopamine is favored as the initial vasopressor with isoproterenol 
most frequentl y added when a second vasopressor became necessary. The renal sparing effect  of 
dopamine makes it a rational first choice as a vasopressor ami the inherent beta agonist effects 
of isoproterenol more directly counteract the hypotension ami bradycardia produced by 
verapamil.2 
Treatment Recommendations 
After describing the 50 AAPCC study cases and comparing the intentional 
verapamil overdoses to those i n the literature, a summary of orpn system effects  follows and 
treatment recommendations are provided for patients acutely overdosing vith verapamil. 
Regardless of the dose ingested, psychiatric intervention should be provided to the patient if the 
overdose intent was purposeful. 
Minor toxicity occurs at doses of < 480 mg. of verapamil for adults and < 80 mg. for 
pediatric patients. Gastrointestinal effects  tray occur; nausea and spontaneous vomiting are 
commonl g reported. Approximately half of the patients develop mild central nervous system 
effects  such as lightheadedness, dizziness, headache, sleepiness or drowsiness, lethargy 
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and ataxia. Transient heart rate changes also occur at these doses; bradycardia is more common 
than tachycardia. Patients i ngesti ng these amounts of verapamil may be observed at home. 
Gastrointestinal decontamination is rot necessary. If these mi nor symptoms develop, they vill 
occur vithin one to tvo hours and should abate vithln six to eight hours of exposure. The 
effects  are transient and medical intervention should not be required. 
Moderate toxicity to verapamil occurs in the adult at doses of verapamil between 
480 mg. ami 800 mg; children develop similar effects  at doses between 80mg. and 240 mg. 
Gastrointesti nal and central nervous system effects  are comparable to those descrl bed at lower 
doses, but more serious cardiovascular effects  occur within these dosage ranges. Hypotension 
will likely be present, however, this effect  may be transient and not all patients require 
treatment. Hypotension requiring a fluid challenge occurred in one adult ingesting 480 mg.and 
an 800 mg.dose required administration of dopamine. The patient should be transported to a 
health care facility; if transport by private vehicle will delay treatment longer than twenty 
minutes, ambulance transport should be utilized because symptoms may develop rapidly. Full 
gastrointestinal decontamination should be performed promptly. Consider lavage over induction 
of emesis with 1 pecac syrup; rapid decontamination is necessary since cardiovascular 
compromise may develop abruptly. Blow! pressure readings should be taken every 15 minutes 
for the first two to four hours. If hypotension develops, intravenous fluids and vasopressors 
may be necessary subsequent to placing the patient in the Trendelenberg position. Dopamine 
and isoproterenol have been used most frequently to increase the blood pressure. 
Pharmacologically, a beta agonist vasopressor should be considered to lost counteract CCS 
toxicity. The administration of calci urn salts may be tried to i ncrease the blood pressure and 
and ataxia. Transient heart rate changes also occur at these doses; bradycardia is mere common 
than tachycardia. Patients ingesting these amounts of verapamil may be observed at home. 
Gastrointestinal decontamination is not necessary. If these minor symptoms develop, they vil l 
occur vtthln one to tvo hours and should abate vithin six to eight hours of exposure. The 
effects  are transient ami medical intervention should not be required. 
Moderate toxicity to verapamil occurs i n the adult at doses of verapamil between 
480 mg. ami 800 mg; children develop si milar effects  at doses between 80mg. and 240 mg. 
Gastrointestinal arid central nervous system effects  are comparable to those described at lower 
doses, but more serious cardiovascular effects  occur within these dosage ranges. Hypotension 
will likely be present, however, this effect  may be transient and not all patients require 
treatment. Hypotension requiringafluid challenge occurredinoneadultingesting 480 mg.and 
an 800 mg.dose required administration of dopamine. The patient should be transported to a 
health care facility; if transport by private vehicle will delay treatment longer than twenty 
minutes, ambulance transport should be utilized because symptoms may develop rapidly. Full 
gastrointestinal decontamination should be performed promptly. Consider lavage over induction 
of emesis with ipecac syrup; rapid decontamination is necessary since cardiovascular 
compromise may develop abruptly. Blood pressure readings should be taken every 15 minutes 
for the first two to four hours. If hypotension develops, intravenous fluids and vasopressors 
may be necessary subsequent to placing the patient in the Trendelenberg position. Dopamine 
and isoproterenol have been used most frequently to increase the blood pressure. 
Pharmacologically, a beta agonist vasopressor should be considered to best counteract CCB 
toxicity. The administration of calcium salts may be tried to increase the blood pressure and 
heart rate, but they cannot be considered antidotal based on conflicting literature reports and 
lack of documented beneficial effects  in the study cases. Those authors who clai m a therapeutic 
benefit administered 10-20 ml. of 10% calcium gluconate by intravenous infusion. The patient 
must be observed in the emergency department for four to six tours. Admission to the hospital 
is dependent on the severity and duration of the symptoms which develop. 
Major toxicity may occur with doses of verapamil >800 mg. i n adults and >240 mg. i n 
children. In addition to the effects  described at lower doses, metabolic abnormalities such as 
hyperglycemia, acidosis, and hyperkalemia have occurred. Elevated blood glucose 
concentrations may occur due to an inhibition of insulin release 5 5 while acidosis and 
hypergl ycemia cannot be directly linked to verapamil. Severe central nervous system and 
cardiovascular effects  may develop when these doses are exceeded. Patients haw been descri bed 
as agitated, obtunded and unresponsive. Two patients became cyanotic and required intubation 
and electromechanical ventilation. Seizures occurred in an adult who overdosed on 2,000 mg. 
and one child who ingested 400 mg.of verapamil.16 The authors claim a therapeutic benefit 
from administration of calcium salts in treating the seizures which developed in this 11 month 
old child. They gave 2 ml. of 10% calcium chloride which produced "prompt cessation of 
seizure activity" which had been refractory  to tvo previous doses of 50 mg. of 
pherwbarbital given intramuscularly. The cardiovascular system remained refractory  to 
this treatment and ten minutes after ad mi nistration of the calcium the child's blood pressure 
decreased to 38 mm Hg systolic, peripheral pulses became nonpalpable and peripheral 
perfusion was diminished. Dopamine and isoproterenol were infused simultaneously with 
normalization of blood pressure and peripheral perfusion. Arrhythmias may also occur when 
these doses of verapamil are exceeded; supraventricular arrhythmias are common although 
ventricular abnormalities have also been reported. Bradyarrhythmias may develop and 
appear difficult  to manage. 
Death occurred vith an estimated 1 ngestion of 1,600 mg. in a fifteen month old child and 
1,920 mg. in an adult, but survival has occurred in 13 adult patients ingesting larger amounts 
vho received early gastrointestinal decontamination and supportive treatment in the hospital 
setting; one patient had ingested 6,400 mg. ofverapamil. A patient ingesting these large 
amounts of verapamil should be transported by ambulance to a health care facility and promptly 
receive full gastroi ntesti nal decontami nation as previousl y descri bed. I nsuli n may be 
necessary to treat hyperglycemia and solium bicarbonate may be needed if the patient becomes 
acidotic. Anticonvulsants may be required to treat seizures. Intravenous diazepam is 
considered the anticonvulsant of choice for treatment of drug Induce! seizures, however, the 
possible benefit of calcium salts in treating seizures has been described. The blood pressure 
should be continuously monitored and more invasive procedures such as placement of an arterial 
line may be necessary. Previously recommended treatments for hypotension should be 
employed. The patient should also receive constant cardiac monitoring. Pace ma king devices 
may be required to treat bradycardia; atropine does not appear to effective!yincrease  the heart 
rate in these patients. Additional life-sustaining therapy may be required. Intubation, 
electromechanical ventilation and CPR have been utilized. The patient should be admitted to an 
1 ntensive care unit for continued symptomatic and supportive care. Recovery time has ranged 
from six hours to three days; most patients appeared to improve after 12 hours of intensive care 
management and monitori ng. 
SUMMARY 
This author has reviewed, summarized and described the characteristics, symptoms, 
treatment ami outcome of acute ingestions of the CCB agents verapamil, nifedipine and diltiazem 
from cases reported to the AAPCC during 1984. This description vas achieved through i 
retrospective review of the medical record portion of 50 AAPCC Cooperative Poison Center 
Report Forms submitted by poison centers collecting data for the calendar year 1984. This is 
the flrst comprehensive description of poisoni ng cases involving CCB agents and the first use of 
the AAPCC National Data Base for this purpose. 
On average, patientsingesting diltiazem and nifedipine ingested amounts within the 
recommended daily therapeutic range, unli ke those who ingested verapamil and took greater than 
five times the upper limit of acceptable daily therapeutic doses. Therefore,  the caws 
exhibiting serious toxicity are composed of verapamil overdoses. Patients 1 ngesti ng nlfedl pi ne 
developed central nervous system effects  at a greater rate than those exposed to verapamil and 
diltiazem, which is consistent with the side effect  profile of nifedipine at therapeutic doses. 
Further research must be performed before calcium can be considered as an antidote for 
an acute overdose of a CCB agent. Although the literature reports claim a therapeutic benefit 1n 
treating hypotension and even seizures, these findings could not be confirmed in the study cases. 
Ten suicidal literature cases involving verapamil were reviewed and compared to 15 
suicidal verapamil exposures in the AAPCC series, This extensive review hss culminated in the 
description of toxic ranges and provision of  treatment recommendations as guidelines for the 
health care professional treating a patient who has ingested a large amount of verapamil. 
ILLUSTRATIONS 
481 TOTAL CCB EXPOSURES IN NATIONAL DATABASE 
- 242 NO EFFECT (ASYMPTOMATIC) 
- 39 CASES FROM CENTERS NOT PARTICIPATING 
- 11 CASES NOT RETRIEVABLE BY POISON CENTERS 
- 10 CASES UNAVAILABLE DUE TO CLERICAL ERRORS 
- 71 UNKNOWN OUTCOMES 
- 43 POLYDRUG EXPOSURES 
7 INGESTiON OF OTHER THAN CCB 
5 NON-AAPCC FORM 
I DRU6 INFORMATION REQUEST 
1 DUPLICATE CASE 
1 ANIMAL EXPOSURE 
50 STUDY CASES DESCRIBED 
FIGURE 1 FLOW CHART FOR EXCLUSI ON OF CASES FROM STUDY 
TABLE I 
« 
AGE AND SEX DISTRIBUTION AND EXPOSURE INTENT BY PRODUCT 
ACCIDENTAL ADVERSE REACTION INTENTIONAL OVERDOSE 
PRODUCT Males Females Males Females Males Females 
DILT1AZEM 1 1 
CHILDREN NIFEDIPINE 1 4 
<5 yrs, 
VERAPAMIL1 6 3 
DILTIAZEM 1 2 - 1 1 
ADULTS NIFEDIPINE 1 2 1 2 2 
>15 yrs. 
VERAPAMIL 1 3 1 4 11 
1 The sex of ore child ingesting verapamil vas not recorded. 
TABLE I! 
TIME BETWEEN INGESTION AND POISON CENTER CONTACT 
FOR PATIENTS WITH KNOWN INGESTION TIMES (N=38) 1 
TIME ADULTS CHILDREN TOTAL COM. TOTAL 
DELAY * { % ) * ( % ) * ( % ) * (%) 
<5 MIN. 4 (16 .7 ) 4 ( 2 8 . 6 ) 8 (21 .0 ) 8 (21.0) 
5MIN. 1 (4.2) 4 ( 2 8 . 6 ) 5 (13 .1 ) 13 (34.2) 
10 MIN. 1 (4.2) 2 ( 1 4 . 3 ) 3 (7.9) 16 (42.1) 
30 MIN. 3 (12 .5 ) 3 ( 2 1 . 4 ) 6 (15 .8 ) 22 (57.9) 
60 MIN. 5 (20 .8 ) 0 5 (13 .1 ) 27 (71.0) 
120 MIN. 3 (12 .5 ) 1 (7 .1) 4 (10 .5 ) 31 (81.5) 
180 MIN. 2 (8.3) 0 2 (5.3) 33 (86.8) 
240 MIN. 2 (8.3) 0 2 (5.3) 35 (92.1) 
360 MIN. 2 (8.3) 0 2 (5.3) 37 (97.4) 
>360 MIN. 1 (4.2) 0 1 (2.6) 38 (100.0) 
1 Excl uded from this table are four patients vho Ingested the CCB over a chronic 
period of time and eight patients for vhom the time between ingestion and 
poison center contact was unknown. 
TABLE I i I 
DOSE INGESTED BY PRODUCT AND AGE CATEGORY 
PRODUCT MEAN RANGE THERAPEUTIC RANGE 
DILTIAZEM (N=2) 38 MG 15-60 MG 
CHILDREN NIFEDIPINE (N»3) 10 MG 1QMG NOT AVAILABLE 
< 5 yrs. VERAPAMIL (N=6) 710MG 40-1,600 MG 
DILTIAZEM <N«3) 60 MG 60 MG 180-240 MG/DAY 
ADULTS NIFEDIPINE (N=7) 87 MG 10-300MG 120-180MG/DAY 
>15 yrs. VERAPAMIL (N= 16} 2,871 MG 180-21,600 MG 320-480 MG/DAY 
TABLE IV 
TOXIC EFFECTS BY ORGAN SYSTEM IN STUDY CASES 1 
ORGAN SYSTEM ADULTS CHILDREN. TOTAL 
(N=33) (N=13)2 (N=50) 
# * * ( % ) 
CARDIOVASCULAR 
HR Change3 11 0 11 (22.0) 
Hypotension 17 2 19 (38.0) 
Arrhythmias 10 3 13 (26.0) 
CNS 4 21 3 24 ( 48.0) 
DERMAL5 2 2 4 (8.0) 
G i 6 7 4 1 1 (22.0) 
OTHER7 3 1 4 (8.0) 
Total percentage exceeds 100% because some pat ients had more 
than one organ system affected. 
The remaining four chi ldren vomited a f te r  receiving ipecac syrup. 
A l l pat ients Ingested verapamil. 
includes lightheadedness, dizziness, headache, shakiness, lethargy, 
sleepiness or drowsiness, ataxia, ag i ta t ion and combativeness. 
Incluaes red l ips, red cheeks, f lushing, petecchiae, and a macular 
rash w i t h p rur i t i s . 
Includes nausea and vomi t ing and one case of acute gast ro intest ina l 
hemorrhage reported on autopsy; a l l symptoms occurred pr ior to 
adminst ra t ion of gast ro intest ina l decontaminat ion measures. 
Includes one adult w i t h hyperglycemia and another adult w i t h 
cyanosis, a t h i r d adult w i t h d ig i ta l ischemia, a ch i ld w i t h 
hyperkalemia, acute renal fa i lure and adult respiratory d is t ress 
syndrome; due to the complexi ty of the case, these ef fects  cannot 
be de f in i t i ve ly a t t r i bu ted to the CCB. 
TABLE V 
TREATMENT SITE AND DISPOSITION OF STUDY SUBJECTS 
HCF1 non-HCF2 
REASON ADMITTED TREATED & RELEASED DIED 
CHILDREN ACCIDENTAL 5 5 1 6 
ACCIDENTAL/ 1 6 - 8 
ADYERSE REACTION 
ADULTS 
INTENTIONAL I S 3 1 2 
OVERDOSE 
TOTAL 21 12 3 14 
1 Incl udes all patients evaluated at a health care facility. 
2 Incl udes subjects observed at home and those instructed to inform their private physician. 
3 One subject vas admitted for psychiatric evaluation. 
TABLE VI 
GASTROINTESTINAL DECONTAMINATION METHODS 
USED IN STUDY CASES 1 
TREATMENT ADULTS CHILDREN TOTAL 
* * * ( % ) 
IPECAC SYRUP 5 11 1 6 ( 3 2 . 0 ) 
LAVAGE 4 1 5 (10.0) 
ACTIVATED CHARCOAL 9 2 11 (22.0) 
CATHARTIC 4 3 7 (14.0) 
FULL DECONTAMINATION2 2 2 4 (8.0) 
' Percentage does not to ta l 100% because some pat ients received more 
than one t reatment and others did not receive t reatment ; 22 pat ients 
received some form of gast ro in tes t ina l decontamination. 
2 Includes ipecac or lavage, act ivated charcoal and a cathart ic . 
TABLE VII 
SPECIFIC TREATMENTS USED IN STUDY CASES 1 
TREATMENT ADULTS CHILDREN T0TA1 
(N-33) (N= 17) (N=50) 
# * * (%) 
CALCIUM SALTS2 6 1 
i 
7 (14.0) 
r JJ iD uHALLENGt 7 0 7 (14.0) 
VASOPRESSORS2 9 0 9 (18.0) 
CARDIAC PACING2 2 0 2 (4.0) 
CARD10PULM, RESUSC 2 2 1 3 (5.0) 
DEFIBRILLATION2 1 0 1 (3.0) 
OTHER3 6 0 6 (12.0) 
• Percentage does not to ta l 100% because some pat ients received more 
than one t reatment and others did not require t reatment ; 21 pat ients 
received these treatments. 
2 A l l pat ients Ingested verapamil. 
3 Includes extracorporeal removal, l idocaine, Insul in, oral f luids, 
an t ih is tamines and a topical steroid cream. 
APPENDIX A 
AAPCC COOPERATIVE POISON CENTER REPORT FORM 
APPENDIX B 
SAMPLE LETTER SENT TO POISON CENTERS 
ECCLES HEALTH SCIENCES LIBRARY 
SO North Medical Drive, Building 
Sill Laki City, Utih 84132 
The Interrnountain Regional 
POISON CONTROL CENTER 
J, C, Veltr i , Pharm.D. 
Interaountain Reg, PCC 
50 North Medical Drive 
Salt Lake City, UT 84132 
Dear Doctor Meltri; 
You recently agreed to release your center code for an investigation of calcium channel 
blocker exposures during 1984. As the principle investigator of this study, 3 an 
requesting your cooperation in obtaining Bore detailed inforriation about the cases. My 
research project is a requirement for the Doctor of Pharmacy degree at the University of 
Utah and the objective of my study is to describe the detiographic characteristics, 
frequency, and severity of acute ingestions involving calcium channel blocking agents 
(verapamil, diltiazen, nifedipine). 3 expect to achieve this goal through a retrospective 
review of the original nedical record portion of the AAPCC Data Collection Form. 
The following synptcmatic cases were reported by your center; 
Fornt Date Hour Drug 






I t would be most helpful if you could locate the medical record portion of the forms, 
photocopy then, and send the copies to ne in the enclosed envelope. 
Investigational Review Board approval has been obtained from the University of Utah. 
Patient confidentiality is assured. Please be informed that strict confidence will be 
maintained and no attempt will be made to contact the subject, You nay, however, 
blacken names and phone numbers before forwarding the photocopies. I am requesting 
photocopies of the forms to allow retrieval of data which are not captured on the data 
collection portion (dose, synptoms manifested, etc . ) . 
1 sincerely hope you can find tine to assist ne in this research endeavor, If 
questions arise or you ire unable to comply with ray request, please contact ne i t the 
Interisountain Regional Poison Control Center so that alternative means of accessing the 
data can be arranged: 1-8Q£M62-Q!M2, 
Respectfully, 
Mary A, NcCoraicK 
Poison Information Pharmacist 
Interaountain Regional Poison Control Center 
Designated as a Regional Poison Control Center by the American Association of Poison Control Centers 
Program o! the Utah Depirtment of Health Family Services Division 
APPENDIX C 
CASE REPORTS OF DEATHS DUE TO VERAPAMIL 
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Three of tte four deaths reported in the AAPCC database in 1984 vere included 
i n the study cases; one of the fatal cases vas excl uded from this re part because the 
patient's chart indicated she had concurrently ingested metoprolol andeimetidine. The 
history, symptoms and treatment course of these patients follow. 
Cam : A 37 year old female arrived at an emergency room at 14:12 and 
was described as combative and moaning occasionally with fixed and dilated pupils. The 
patient had been put to bed by family members after falling from a ladder onto a broken 
table and vhen checked on later vas found in this condition. A prescription for 
verapamil filled the day before vas found nearby and the amount ingested vas estimated 
at 1,920 mg., although the time of ingestion vas unknown. After arrival, the patient 
vas cyanotic, hypotensive, and bradycardlc with a pulse of 32; orbital ami nasal 
fractures were noted as were hematomas of the left breast ami cheek. The patient vas 
endotracheal! y intubated and mechanically ventilated, intravenous isoproterenol was 
initiated, and a central venous pressure line and pacemaker were inserted shortly 
after arrival at the emergency department. The patient was cardioverted tvice for 
ventricular fibrillation. Norepinephrine was added to the isoproterenol as a pressor 
agent, however, the patient continued to deteriorate and cardiopulmonary resuscitation 
(CPR) was im'tiated. CPR was stopped approximately 30 minutes after initiation and 
the patient was pronounced dead. 
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Case *2: The poison center vas called by a physician regarding a 15 month 
old malevho had possibly ingested 1,600 mg. of verapamil five hours prior the to call. 
The child vas descri bed as "unstable" in the Intensive care unit. Nine hours after 
ingestion the child's condition apparently deteriorated and he experienced a cardiac 
arrest and vas noted to have a serum potassium of 10 mEq/1. A follow-up call placed 
by the poison center 12 hours after exposure determined that the child had died. 
Pathological findings according to the medical exami ner's report vere multiple cardiac 
arrhythmias ami clinical hypotension, adult respiratory distress syndrome, hypoxic 
encephalopathy, acute renal failure and diffuse gastrointestinal hemorrhage. 
Case * 3 : The dispatcher for paramedics at the scene contacted the poison 
center about a 35 year old male vho had allegedly i ngested 21,600 mg. of verapamil 
one-half hour prior to the call. At 11:30 the receiving emergency room descri bed the 
patient as "initially stable in the field", but a widened QRS interval vas noted on arrival 
in the emergency room. Calcium chloride (dose unknovn) vas given and apparently 
corrected the electrocardiographic abnormality. The systolic blood pressure vas 
50-60 mm Hg, do pa mine awl isoproterenol vere administered and a cardiac pacemaker 
was placed in the patient. At 14:10 the emergency room reported that the patient had 
expired after experiencing third degree heart block and a junctional rhythm prior to 
asystole. Resuscitation efforts  failed. 
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